<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04208087</url>
  </required_header>
  <id_info>
    <org_study_id>722/1121</org_study_id>
    <nct_id>NCT04208087</nct_id>
  </id_info>
  <brief_title>PK and Safety of SI-722 in IC/BPS</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of SI-722 Intravesical Instillation in Interstitial Cystitis/Bladder Pain Syndrome Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seikagaku Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seikagaku Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed randomized, double-blind, placebo-controlled trial in Interstitial&#xD;
      Cystitis/Bladder Pain Syndrome patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2020</start_date>
  <completion_date type="Actual">January 12, 2021</completion_date>
  <primary_completion_date type="Actual">January 12, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>4 weeks</time_frame>
    <description>To assess Cmax after single dose of SI-722</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach the Maximum observed plasma concentration (Tmax)</measure>
    <time_frame>4 weeks</time_frame>
    <description>To assess tmax after dose of SI-722</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative amount of drug excreted in urine (Ae)</measure>
    <time_frame>4 weeks</time_frame>
    <description>To assess Ae after dose of SI-722</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>4 weeks</time_frame>
    <description>To assess the incidence of treatment-related adverse events after dose of SI-722</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cystoscopy</measure>
    <time_frame>4 weeks</time_frame>
    <description>To assess abnormal change from baseline in cystoscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinical significant change in vital signs, electrocardiograms and clinical laboratory assessments</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of participants with clinical significant change in vital signs, electrocardiograms and clinical laboratory assessments will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject Diary</measure>
    <time_frame>4 weeks</time_frame>
    <description>To assess change from baseline in bladder pain, symptoms, voiding frequency and voiding volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interstitial Cystitis Symptom Index Score/Problem Index Score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Interstitial Cystitis Symptom Index Score/Problem Index Score (ICSI/PI) will be used to assess the change from baseline of the symptoms of IC/BPS. ICSI and ICPI have 4-items respectively.&#xD;
Regarding ICSI, each item on the questionnaire is scored from 0 to 5 and this means that a person can score between 0 and 20 for symptom of IC/BPS.&#xD;
Regarding ICPI, each item on the questionnaire is scored from 0 to 4 and this means that a person can score between 0 and 16 for problem of IC/BPS.&#xD;
These higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bladder Pain/Interstitial Cystitis Symptom Score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Bladder Pain/Interstitial Cystitis Symptom Score (BPIC-SS) will be used to assess change from baseline of the symptoms of IC/BPS.&#xD;
Questions 1-7 are scored from 0-4, and question 8 is scored from 0-10. Using these 8 questions, person can score between 0 and 38. These higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Response Assessment</measure>
    <time_frame>4 weeks</time_frame>
    <description>Global Response Assessment (GRA) will be used to assess change from baseline of the symptoms of IC/BPS.&#xD;
This questionnaire includes 7 point scale which is centered at zero (no change): markedly worse; moderately worse; slightly worse; no change; slightly improved; moderately improved; and markedly improved.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Interstitial Cystitis</condition>
  <condition>Bladder Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>SI-722</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SI-722</intervention_name>
    <description>SI-722 will be intravesically instilled.</description>
    <arm_group_label>SI-722</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be intravesically instilled.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females, ≥18 and ≤80 years of age&#xD;
&#xD;
          -  A score of 19 or greater on the Bladder Pain/Interstitial Cystitis Symptom Score&#xD;
             (BPIC-SS)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Urinary tract infection ≤30 days&#xD;
&#xD;
          -  Treatment with intravesical therapy ≤60 days&#xD;
&#xD;
          -  Treatment with any opioid therapy ≤7 days&#xD;
&#xD;
          -  History of bladder hydrodistension ≤3 months&#xD;
&#xD;
          -  Has cancer or a past history of any cancer ≤5 years&#xD;
&#xD;
          -  Body mass index (BMI) ≥40 kg/m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>American Institute of Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TriValley Urology Medical Group</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Medical Associates</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32159</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AccuMed Research Associates</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centex Studies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>December 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bladder</keyword>
  <keyword>Intravesical Injection</keyword>
  <keyword>Interstitial Cystitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

